BBHvsXLVIETF Comparison
VS
ETF 2
XLVI
State Street Health Care Select Sector SPDR Premium Income Fund
This fund is part of
Options Strategies
-0.07%
VanEck Biotech ETF (BBH) belongs to the US Health Care segment. State Street Health Care Select Sector SPDR Premium Income Fund (XLVI) is part of the Options Strategies segment. BBH's top 1 sector exposures are Healthcare. In contrast, XLVI's top sector exposures are Healthcare and Consumer Non-Cyclicals. Both BBH and XLVI have the same Total Expense Ratio (TER) of 0.35%. BBH is up 11.26% year-to-date (YTD) with -$7M in YTD flows. XLVI performs worse with 7.88% YTD performance, and +$10M in YTD flows. Run a side-by-side ETF comparison of BBH and XLVI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBH vs XLVI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 08/05/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBH XLVI | +0.13%+2.21% | +12.94%+10.71% | +11.26%+7.88% | +31.17%+22.83% | +34.53%n/a | -1.53%n/a |
| Flows | BBH XLVI | -+$6M | -$63K+$10M | -$7M+$10M | -$28M+$21M | -$180M- | -$139M- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBH XLVI | +21.11%+11.82% | +19.38%+10.79% | +19.26%n/a | +21.51%n/a |
| Max drawdown | BBH XLVI | -5.29%-2.03% | -10.54%-8.21% | -22.78%n/a | -39.88%n/a |
| Max drawdown duration | BBH XLVI | 29d7d | 150d115d | 440dn/a | 1822dn/a |
Trading data
BBH | XLVI | |
Last sale 8/6/2026 at 1:30 PM | $210.67 | $26.57 |
| Previous close 08/05/2026 | $210.49 | $26.55 |
| Consolidated volume 08/05/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of July 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XLVI
is actively managed and doesn’t replicate an indexBBH | XLVI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 8/6/2026 at 1:30 PM
Live
Closed
BBH | XLVI | |
|---|---|---|
| Last price | $210.67 | $26.57 |
| 1D performance | +0.08% | +0.08% |
| AuM | $409.71 M | $22.29 M |
| E/R | 0.35% | 0.35% |
Characteristics
BBH | XLVI | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | VanEck | State Street Investment Management |
| Benchmark | MVIS US Listed Biotech 25 Index | - |
| N° of holdings | 24 | 59 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 20, 2011 | July 30, 2025 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBH
USA
87.33%
Other
12.67%
XLVI
USA
100.53%
Other
-0.53%
Sectors
BBH
Healthcare
100%
XLVI
Healthcare
100.33%
Other
-0.33%
Advertisement
Diversification
BBH
Total weight of top 15 holdings out of 15
85.08%
XLVI
Total weight of top 15 holdings out of 15
74.76%
Top 15 holdings
Data as of June 30, 2026
BBH
Amgen, Inc.
15.15%
Gilead Sciences, Inc.
12.75%
Vertex Pharmaceuticals, Inc.
9.15%
Regeneron Pharmaceuticals, Inc.
6.26%
Revolution Medicines, Inc.
5.41%
Natera, Inc.
4.92%
argenx SE
4.88%
IQVIA Holdings, Inc.
4.30%
Alnylam Pharmaceuticals, Inc.
3.73%
Biogen, Inc.
3.63%
Moderna, Inc.
3.34%
Illumina, Inc.
3.26%
BeOne Medicines Ltd.
2.85%
United Therapeutics Corp.
2.84%
Insmed, Inc.
2.62%
XLVI
Eli Lilly & Co.
17.01%
Johnson & Johnson
10.96%
AbbVie, Inc.
7.97%
UnitedHealth Group, Inc.
6.77%
Merck & Co., Inc.
5.69%
Amgen, Inc.
3.50%
Thermo Fisher Scientific, Inc.
3.34%
Abbott Laboratories
2.83%
Gilead Sciences, Inc.
2.81%
Intuitive Surgical, Inc.
2.53%
Pfizer Inc.
2.46%
CVS Health Corp.
2.37%
Vertex Pharmaceuticals, Inc.
2.26%
Danaher Corp.
2.15%
Bristol Myers Squibb Co.
2.11%
Frequently asked questions about BBH and XLVI
How have the BBH and XLVI ETFs performed in 2026?
As of August 5, 2026, BBH is up 11.26% year-to-date (YTD), while XLVI has returned 7.88%. That puts BBH better performer ahead so far this year.
Which ETF is attracting more investor money: BBH or XLVI?
Year-to-date, the BBH ETF saw -$7M in flows, compared to +$10M for XLVI.
Which ETF is more volatile: BBH or XLVI?
Over the past year, BBH had a volatility of 19.38%, while XLVI experienced 10.79%.
Which ETF is bigger: BBH or XLVI?
As of August 5, 2026, BBH holds $409.71 M in assets under management (AUM), while XLVI manages $22.29 M.
What sectors do the BBH and XLVI ETFs invest in?
BBH leans toward sectors like Healthcare. Meanwhile, XLVI focuses on Healthcare.
What are the top holdings of the BBH ETF and XLVI ETF?
BBH top holdings include Amgen, Inc., Gilead Sciences, Inc. and Vertex Pharmaceuticals, Inc.. XLVI holds in its top three: Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc..
Which ETF is more diversified: BBH or XLVI?
BBH holds 24 securities with 85.08% of its assets in the top 15. XLVI has 59 securities and a top 15 weight of 74.76%.
Advertisement
Advertisement
